T cells do not have the last word in some breast cancers. According to a study from the University of Pittsburgh, the key to estrogen receptor positive (ER+) breast tumors are macrophages, not T cells, and targeting them could prevent immunotherapy failure in this type of cancer.
An international study led by Australian scientists has shown for the first time that the androgen receptor (AR) is a tumor suppressor in estrogen receptor-positive (ER+) metastatic breast cancer, including in endocrine therapy resistance, which supports the use of an AR agonist-based treatment strategy.
